In the Phase 2 trial, GI side effects were dose-dependent and generally mild to moderate in severity
Research-grade suppliers, compounding platforms, private clinics, and the eventual commercial market all operate in completely different pricing tiers
Consequently, their relative neuroprotective efficacy remains unclear
We think operating income growth could be slightly higher at 29%, also at the high end of managements updated guidance
N-ethylmaleimide is frequently used to trap free thiols, but reagent choice, timing, collection tubes, anticoagulants, storage conditions, and freeze-thaw limits must be validated for the matrix and analytical method
Tirzepatide is more likely to cause nausea than other similar medications (e.g